A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Eftrenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Therapeutic Use
- Acronyms B-SURE
- Sponsors Swedish Orphan Biovitrum
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Oct 2018 Status changed from not yet recruiting to recruiting.
- 06 Sep 2018 New trial record